Ebselen improves ischemia-reperfusion injury after rat lung transplantation

Jürg Hamacher, Uz Stammberger, Elvira Weber, Rudolf Lucas, Albrecht Wendel

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.

Original languageEnglish (US)
Pages (from-to)98-103
Number of pages6
Issue number2
StatePublished - Apr 2009


  • Anti-inflammatory agents
  • Ebselen
  • Lung transplantation
  • Reperfusion injury

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Ebselen improves ischemia-reperfusion injury after rat lung transplantation'. Together they form a unique fingerprint.

Cite this